Skip to main content
Top
Published in: Breast Cancer Research 5/2014

Open Access 01-10-2014 | Research article

Risk of contralateral second primary breast cancer according to hormone receptor status in Germany

Authors: Carsten Rusner, Katharina Wolf, Ulrike Bandemer-Greulich, Jutta Engel, Christa Stegmaier, Bernd Holleczek, Gabriele Schubert-Fritschle, Anett Tillack, Andreas Stang

Published in: Breast Cancer Research | Issue 5/2014

Login to get access

Abstract

Introduction

Hormone receptor (HR) status has become an established target in treatment strategies of breast cancer. Population-based estimates of contralateral breast cancer (CBC) incidence by HR subtype in particular are limited. The aim of this study was to provide detailed data on CBC incidence for Germany.

Methods

Invasive breast cancer data were extracted on 49,804 women yielding 594 second primaries from the cancer registries of the Federal States of Brandenburg and Saarland and the area of Munich for the period from 1998 to 2007. Multiple imputation was used on missing values for HR status. We estimated standardized incidence ratios (SIRs) with 95% confidence intervals (95%CIs).

Results

SIR estimates of CBC among women diagnosed with an invasive first primary breast cancer (FBC) of any HR subtype ranged from 1.0 to 1.5 in the three registries. Pooling three registries’ data, the SIR of HR-positive CBC was 0.7 (95%CI: 0.6 to 0.8) among women with HR-positive FBC. For those women with HR-negative FBC, the SIR of HR-negative CBC was 8.9 (95%CI: 7.1 to 11.1). Among women with FBC diagnosed before the age of 50 years, incidence of CBC was increased, especially for HR-negative FBC (SIR: 9.2; 95%CI: 7.1 to 11.9).

Conclusions

HR status of the first primary and age at first diagnosis is relevant for predicting risk of CBC. Particularly, patients with HR-negative FBC had elevated risks.
Appendix
Available only for authorised users
Literature
1.
go back to reference Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G: Breast cancer. Lancet. 2005, 365: 1727-1741. 10.1016/S0140-6736(05)66546-4.CrossRefPubMed Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G: Breast cancer. Lancet. 2005, 365: 1727-1741. 10.1016/S0140-6736(05)66546-4.CrossRefPubMed
2.
go back to reference Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999, 8: 855-861.PubMed Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999, 8: 855-861.PubMed
3.
go back to reference Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD, Anton-Culver H, Bernstein JL: Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010, 28: 2404-2410. 10.1200/JCO.2009.24.2495.CrossRefPubMedPubMedCentral Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD, Anton-Culver H, Bernstein JL: Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010, 28: 2404-2410. 10.1200/JCO.2009.24.2495.CrossRefPubMedPubMedCentral
4.
go back to reference Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.
5.
go back to reference Li CI, Malone KE, Weiss NS, Daling JR: Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2001, 93: 1008-1013. 10.1093/jnci/93.13.1008.CrossRefPubMed Li CI, Malone KE, Weiss NS, Daling JR: Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2001, 93: 1008-1013. 10.1093/jnci/93.13.1008.CrossRefPubMed
6.
go back to reference Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA: Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009, 101: 1058-1065. 10.1093/jnci/djp181.CrossRefPubMedPubMedCentral Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA: Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009, 101: 1058-1065. 10.1093/jnci/djp181.CrossRefPubMedPubMedCentral
7.
go back to reference Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, Castiglione M, Vinh-Hung V, Vlastos G, Rapiti E: Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2011, 127: 233-241. 10.1007/s10549-010-1137-z.CrossRefPubMed Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, Castiglione M, Vinh-Hung V, Vlastos G, Rapiti E: Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2011, 127: 233-241. 10.1007/s10549-010-1137-z.CrossRefPubMed
8.
go back to reference Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, Czene K: Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study. PLoS One. 2012, 7: e46535-10.1371/journal.pone.0046535.CrossRefPubMedPubMedCentral Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, Czene K: Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study. PLoS One. 2012, 7: e46535-10.1371/journal.pone.0046535.CrossRefPubMedPubMedCentral
9.
go back to reference Good practice of secondary data analysis, first revision. Gesundheitswesen. 2008, 70: 54-60. 10.1055/s-2007-1022529. Good practice of secondary data analysis, first revision. Gesundheitswesen. 2008, 70: 54-60. 10.1055/s-2007-1022529.
10.
go back to reference Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P: Cancer in Five Continents Vol. IX. 2007, IARC Press, Lyon Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P: Cancer in Five Continents Vol. IX. 2007, IARC Press, Lyon
11.
go back to reference Krebs in Deutschland, 7. 2010, Ausgabe, Saarbrücken Krebs in Deutschland, 7. 2010, Ausgabe, Saarbrücken
12.
go back to reference The International Statistical Classification of Diseases and Related Health Problems, Tenth revision. 1992, World Health Organization, Geneva The International Statistical Classification of Diseases and Related Health Problems, Tenth revision. 1992, World Health Organization, Geneva
13.
go back to reference Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S: International Classification of Diseases for Oncology (ICD-O). 2000, World Health Organization, Geneva Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S: International Classification of Diseases for Oncology (ICD-O). 2000, World Health Organization, Geneva
15.
go back to reference Janssen KJ, Donders AR, Harrell FE, Vergouwe Y, Chen Q, Grobbee DE, Moons KG: Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol. 2010, 63: 721-727. 10.1016/j.jclinepi.2009.12.008.CrossRefPubMed Janssen KJ, Donders AR, Harrell FE, Vergouwe Y, Chen Q, Grobbee DE, Moons KG: Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol. 2010, 63: 721-727. 10.1016/j.jclinepi.2009.12.008.CrossRefPubMed
16.
go back to reference Little RJA, Rubin DB: Statistical Analysis with Missing Data (Second Edition). 2002, John Wiley & Sons, New York Little RJA, Rubin DB: Statistical Analysis with Missing Data (Second Edition). 2002, John Wiley & Sons, New York
17.
go back to reference Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004, 96: 516-523. 10.1093/jnci/djh097.CrossRefPubMed Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004, 96: 516-523. 10.1093/jnci/djh097.CrossRefPubMed
18.
go back to reference Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, Czene K: Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Res Treat. 2012, 134: 793-800. 10.1007/s10549-012-2096-3.CrossRefPubMed Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, Czene K: Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Res Treat. 2012, 134: 793-800. 10.1007/s10549-012-2096-3.CrossRefPubMed
19.
go back to reference Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI: Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat. 2012, 135: 849-855. 10.1007/s10549-012-2183-5.CrossRefPubMedPubMedCentral Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI: Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat. 2012, 135: 849-855. 10.1007/s10549-012-2183-5.CrossRefPubMedPubMedCentral
20.
go back to reference Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G: Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast. 2012, 21: 20-26. 10.1016/j.breast.2011.09.006.CrossRefPubMed Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G: Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast. 2012, 21: 20-26. 10.1016/j.breast.2011.09.006.CrossRefPubMed
21.
go back to reference Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.
22.
go back to reference Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, et al: Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013, 31: 3091-3099. 10.1200/JCO.2012.47.8313.CrossRefPubMedPubMedCentral Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, et al: Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013, 31: 3091-3099. 10.1200/JCO.2012.47.8313.CrossRefPubMedPubMedCentral
23.
go back to reference Van Ewijk RJ, Schwentner L, Wockel A, Konig J, Kreienberg R, Blettner M: Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet. 2013, 287: 103-110. 10.1007/s00404-012-2544-7.CrossRefPubMed Van Ewijk RJ, Schwentner L, Wockel A, Konig J, Kreienberg R, Blettner M: Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet. 2013, 287: 103-110. 10.1007/s00404-012-2544-7.CrossRefPubMed
24.
go back to reference Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011, 378: 771-784. 10.1016/S0140-6736(11)60993-8.CrossRefPubMed Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011, 378: 771-784. 10.1016/S0140-6736(11)60993-8.CrossRefPubMed
25.
go back to reference Arpino G, Weiss H, Lee AV, Schiff R, De PS, Osborne CK, Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005, 97: 1254-1261. 10.1093/jnci/dji249.CrossRefPubMed Arpino G, Weiss H, Lee AV, Schiff R, De PS, Osborne CK, Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005, 97: 1254-1261. 10.1093/jnci/dji249.CrossRefPubMed
26.
go back to reference Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004, 22: 2328-2335. 10.1200/JCO.2004.04.033.CrossRefPubMed Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004, 22: 2328-2335. 10.1200/JCO.2004.04.033.CrossRefPubMed
27.
go back to reference Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009, 27: 5887-5892. 10.1200/JCO.2008.19.9430.CrossRefPubMed Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009, 27: 5887-5892. 10.1200/JCO.2008.19.9430.CrossRefPubMed
28.
go back to reference Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.CrossRefPubMed Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.CrossRefPubMed
29.
go back to reference Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA: A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1534-1538. 10.1158/1055-9965.EPI-05-0070.CrossRefPubMed Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA: A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1534-1538. 10.1158/1055-9965.EPI-05-0070.CrossRefPubMed
30.
go back to reference Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N: Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat. 2014, 144: 133-142. 10.1007/s10549-014-2842-9.CrossRefPubMedPubMedCentral Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N: Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat. 2014, 144: 133-142. 10.1007/s10549-014-2842-9.CrossRefPubMedPubMedCentral
31.
go back to reference Sluyser M, Wittliff JL: Influence of estrogen receptor variants in mammary carcinomas on the prognostic reliability of the receptor assay. Mol Cell Endocrinol. 1992, 85: 83-88. 10.1016/0303-7207(92)90127-R.CrossRefPubMed Sluyser M, Wittliff JL: Influence of estrogen receptor variants in mammary carcinomas on the prognostic reliability of the receptor assay. Mol Cell Endocrinol. 1992, 85: 83-88. 10.1016/0303-7207(92)90127-R.CrossRefPubMed
32.
go back to reference Rhodes A, Sarson J, Assam EE, Dean SJ, Cribb EC, Parker A: The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010, 134: 621-632. 10.1309/AJCPOG3O3KTPZQNK.CrossRefPubMed Rhodes A, Sarson J, Assam EE, Dean SJ, Cribb EC, Parker A: The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010, 134: 621-632. 10.1309/AJCPOG3O3KTPZQNK.CrossRefPubMed
Metadata
Title
Risk of contralateral second primary breast cancer according to hormone receptor status in Germany
Authors
Carsten Rusner
Katharina Wolf
Ulrike Bandemer-Greulich
Jutta Engel
Christa Stegmaier
Bernd Holleczek
Gabriele Schubert-Fritschle
Anett Tillack
Andreas Stang
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-014-0452-4

Other articles of this Issue 5/2014

Breast Cancer Research 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine